Clinical Trial for Prevention of Cisplatin-Induced Renal Nephrotoxicity

An Exploratory Study to Evaluate the Efficacy and Safety of a Cisplatin Metabolism-Related Enzyme Inhibitor in Cisplatin-Induced Nephrotoxicity

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041220021

Enrollment

Registered

2022-05-25

Start date

2024-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

flopropione dosing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Has provided written consent for participation - Age 18 or greater at the time of consent - Has never received cisplatin-containing chemotherapy - Scheduled for chemotherapy with cisplatin only or cisplatin plus other one- or two- anticancer agents under hospitalization - Lung, head and neck, and other cancer patients scheduled for cisplatin regimens with doses of 75 mg/m2 or higher in patients with

Exclusion criteria

Exclusion criteria: - Presence of renal dysfunction: eGFR<60 mL/min/1.73 m2 - Pregnant or possibly pregnant women - Lactating women - With a history of hypersensitivity to flopropione - Deemed ineligible for the study as determined by the principal investigator or a co-investigator

Design outcomes

Primary

Measure	Time frame
Occurrence of adverse events	—

Secondary

Measure	Time frame
Changes in cisplatin-induced nephrotoxicity markers	—

Contacts

Public ContactTakenao Koseki

Fujita Health University

tkoseki@fujita-hu.ac.jp+81-562-93-9563

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026